
Tracy L Putoczki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7965863/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Emerging roles for IL-11 in inflammatory diseases. Cytokine, 2022, 149, 155750.	3.2	31
2	Fecal DNA Virome Is Associated with the Development of Colorectal Neoplasia in a Murine Model of Colorectal Cancer. Pathogens, 2022, 11, 457.	2.8	7
3	Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival. Cancers, 2021, 13, 559.	3.7	31
4	Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome. Journal of Allergy and Clinical Immunology, 2021, 148, 585-598.	2.9	20
5	The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. Cancers, 2021, 13, 4979.	3.7	9
6	Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11. Frontiers in Immunology, 2020, 11, 1424.	4.8	60
7	A Biobank of Colorectal Cancer Patient-Derived Xenografts. Cancers, 2020, 12, 2340.	3.7	13
8	The structure of the extracellular domains of human interleukin 11α receptor reveals mechanisms of cytokine engagement. Journal of Biological Chemistry, 2020, 295, 8285-8301.	3.4	33
9	Loss of NFKB1 Results in Expression of Tumor Necrosis Factor and Activation of Signal Transducer and Activator of Transcription 1 to Promote Gastric Tumorigenesis in Mice. Gastroenterology, 2020, 159, 1444-1458.e15.	1.3	18
10	Inhibition of the SRC Kinase HCK Impairs STAT3-Dependent Gastric Tumor Growth in Mice. Cancer Immunology Research, 2020, 8, 428-435.	3.4	24
11	Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clinical Science, 2020, 134, 2091-2115.	4.3	59
12	SIDT2 RNA Transporter Promotes Lung and Gastrointestinal Tumor Development. IScience, 2019, 20, 14-24.	4.1	17
13	<p>Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies</p> . OncoTargets and Therapy, 2019, Volume 12, 635-645.	2.0	124
14	TCF-1 limits the formation of Tc17 cells via repression of the MAF–RORγt axis. Journal of Experimental Medicine, 2019, 216, 1682-1699.	8.5	48
15	The expanding role of innate lymphoid cells and their T-cell counterparts in gastrointestinal cancers. Molecular Immunology, 2019, 110, 48-56.	2.2	15
16	Could the inhibition of IL-17 or IL-18 be a potential therapeutic opportunity for gastric cancer?. Cytokine, 2019, 118, 8-18.	3.2	17
17	Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner. Cancer Immunology Research, 2018, 6, 409-421.	3.4	31
18	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. Seminars in Cancer Biology, 2018, 52, 241-252.	9.6	12

TRACY L PUTOCZKI

#	Article	IF	CITATIONS
19	In Vivo Models of Inflammatory Bowel Disease and Colitis-Associated Cancer. Methods in Molecular Biology, 2018, 1725, 3-13.	0.9	10
20	Characterization of Blimp-1 function in effector regulatory T cells. Journal of Autoimmunity, 2018, 91, 73-82.	6.5	36
21	Loss of NF-κB1 Causes Gastric Cancer with Aberrant Inflammation and Expression of Immune Checkpoint Regulators in a STAT-1-Dependent Manner. Immunity, 2018, 48, 570-583.e8.	14.3	61
22	Mutations in Craniosynostosis Patients Cause Defective Interleukin-11 Receptor Maturation and Drive Craniosynostosis-like Disease in Mice. Cell Reports, 2018, 25, 10-18.e5.	6.4	31
23	<i>MACROD2</i> Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors. Cancer Discovery, 2018, 8, 988-1005.	9.4	55
24	STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. Molecular and Cellular Endocrinology, 2017, 451, 15-23.	3.2	49
25	Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression. Cancer Cell, 2017, 31, 563-575.e5.	16.8	57
26	IL-11 is a crucial determinant of cardiovascular fibrosis. Nature, 2017, 552, 110-115.	27.8	451
27	Interleukin-11 classic but not trans-signaling is essential for fertility in mice. Placenta, 2017, 57, 13-16.	1.5	17
28	Mouse models for gastric cancer: Matching models to biological questions. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1257-1272.	2.8	37
29	Complementarity and redundancy of IL-22-producing innate lymphoid cells. Nature Immunology, 2016, 17, 179-186.	14.5	211
30	Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice. Journal of Visualized Experiments, 2015, , .	0.3	6
31	IL-11 signaling as a therapeutic target for cancer. Immunotherapy, 2015, 7, 441-453.	2.0	73
32	Confocal laser endomicroscopy to monitor the colonic mucosa of mice. Journal of Immunological Methods, 2015, 421, 81-88.	1.4	22
33	Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer. Cytokine and Growth Factor Reviews, 2015, 26, 489-498.	7.2	98
34	Glycoprotein A33 deficiency: a new model of impaired intestinal epithelial barrier function and inflammatory disease. DMM Disease Models and Mechanisms, 2015, 8, 805-15.	2.4	28
35	Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. Cancer Biology and Therapy, 2014, 15, 623-632.	3.4	27
36	IL-17 Cuts to the Chase in Colon Cancer. Immunity, 2014, 41, 880-882.	14.3	16

TRACY L PUTOCZKI

#	Article	IF	CITATIONS
37	Molecular Pathways: IL11 as a Tumor-Promoting Cytokine—Translational Implications for Cancers. Clinical Cancer Research, 2014, 20, 5579-5588.	7.0	67
38	The structure of human interleukin-11 reveals receptor-binding site features and structural differences from interleukin-6. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 2277-2285.	2.5	47
39	Epithelial gp130/Stat3 functions: An intestinal signaling node in health and disease. Seminars in Immunology, 2014, 26, 29-37.	5.6	54
40	Interleukin-11 Is the Dominant IL-6 Family Cytokine during Gastrointestinal Tumorigenesis and Can Be Targeted Therapeutically. Cancer Cell, 2013, 24, 257-271.	16.8	341
41	TCF-1 Controls ILC2 and NKp46+RORÎ ³ t+ Innate Lymphocyte Differentiation and Protection in Intestinal Inflammation. Journal of Immunology, 2013, 191, 4383-4391.	0.8	122